describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism on anticoagulant therapy who have changed their therapeutic regimen, due to any clinical situation, based on the doctor's routine clinical practice and are currently on treatment with a direct oral anticoagulant (DOAC)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Composite of demographic characteristics: age, gender and race
Timeframe: At baseline visit
Composite of relevant cardiovascular events: stroke, TIA, systemic embolism, bleeding
Timeframe: At baseline visit
Composite of comorbidities: hypertension, heart failure, diabetes mellitus, kidney failure, dyslipidemia,
Timeframe: At baseline visit
Data on the Non-Valvular Atrial Fibrillation treatment: relevant active substances
Timeframe: At baseline visit
Concomitant treatments: relevant active substances
Timeframe: At baseline visit
Risk of thromboembolic event based on the CHADS2 score
Timeframe: At baseline visit
Risk of thromboembolic event based on the CHA2DS2-VASc score
Timeframe: At baseline visit
Risk of bleeding based on the HAS-BLED score
Timeframe: At baseline visit